Sunovion Seizure Drug Accepted for FDA Review

The pharmaceutical firm has resubmitted STEDESA, a once-daily adjunctive therapy for partial-onset seizures, for review by the agency.

Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application resubmission for STEDESA (eslicarbazepine acetate) for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years and older with epilepsy. STEDESA is the proposed trade name for eslicarbazepine acetate.

No votes yet
Syndicate content